Targeting eosinophils: severe asthma and beyond
This review summarizes the rationale for the use of biologics in eosinophilic diseases and their mechanisms of action.
Back to homepage
Immunology
Guselkumab for the treatment of psoriasis – evidence to date
This review highlights the evidence available to date for the use of guselkumab for the treatment of psoriasis. The results of the recent ECLIPSE trial are addressed.
Novel therapeutic targets for allergic airway disease in children
Keywords: allergic airway disease, allergic rhinitis, asthma, biologics, children, chronic rhinosinusitis, immunotherapy. Citation: Giallongo A, Parisi GF, Licari A, Pulvirenti G, Cuppari C, Salpietro C, Marseglia GL, Leonardia S. Novel therapeutic targets for allergic airway disease in children. Drugs in
Brodalumab in psoriasis: evidence to date and clinical potential
This article reviews brodalumab’s place in the expanding armamentarium of cytokine-directed therapies for patients with severe psoriasis.
Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?
This article is an indirect comparison among literature data, especially between OCS reduction studies (ZONDA-SIRIUS) and pivotal studies (SIROCCO-MENSA), evaluating whether the clinical efficacy and the steroid-sparing effect of benralizumab may represent an advantage over other compounds. This data could help the clinician in the decision process of treatment choice, within the different available therapeutic options for eosinophilic refractory severe asthma.
